Reuters first to report COVID vaccine production in India

Reuters was first to report that Pfizer Inc has told the Indian government it wants to produce its coronavirus vaccine locally if assured of faster regulatory clearance and freedom on pricing and exports. The U.S. company pulled an application last month seeking emergency approval for its product in India after the drug regulator declined its request to skip a small local safety trial. That has kept its vaccine out of one of the world’s biggest drug markets. Reuters also exclusively reported that a first ever leaders’ meeting of the Quad group of countries –  the U.S., Japan, Australia and India – plans to announce financing agreements to support an increase in manufacturing capacity for coronavirus vaccines in India.

Article Tags
Topics of Interest: Health
Type: Reuters Best
Sectors: EquitiesScience
Regions: Asia
Countries: India
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Important Regional Story
Sign up for email updates

Sign up for email updates